Cart
sales@molnova.com
Camonsertib
CAS No. 2417489-10-0
Camonsertib( —— )
Catalog No. M35617 CAS No. 2417489-10-0
Camonsertib (RP-3500) is a novel, potent and selective ATR kinase inhibitor (ATRi) that exhibits potent antitumor effects with an IC50: 1.00 nM in biochemical assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 261 | Get Quote |
|
| 5MG | 416 | Get Quote |
|
| 10MG | 605 | Get Quote |
|
| 25MG | 914 | Get Quote |
|
| 50MG | 1214 | Get Quote |
|
| 100MG | 1638 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCamonsertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionCamonsertib (RP-3500) is a novel, potent and selective ATR kinase inhibitor (ATRi) that exhibits potent antitumor effects with an IC50: 1.00 nM in biochemical assays.
-
DescriptionCamonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity.
-
In VitroWestern Blot AnalysisCell Line:LoVo and CW-2 human colon cancer cell lines Concentration:1 μM Incubation Time:1, 2, 4, 6, 8, 16, 24 hours Result:Inhibited CHK1(Ser345) phosphorylation from 1 to 3 hours. Starting at 4 hours, CHK1(Ser345) became re-phosphorylated as DNA-PKcs became activated in treated cells, along with its substrates KAP1 and H2AX.
-
In VivoAnimal Model:Female mice (6-8 weeks old) bearing LoVo xenograftsDosage:3, 7, 15 mg/kg (0.5% methylcellulose/0.02% SDS vehicle) Administration:Orally; once daily for 18 days Result:Produced dose-dependent tumor growth inhibition with a minimum effective dose (MED) of 7 mg/kg. The maximum tolerated dose (MTD) was 10 mg/kg once daily on a continuous dosing schedule.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetATM/ATR
-
RecptorATM/ATR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2417489-10-0
-
Formula Weight410.47
-
Molecular FormulaC21H26N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (121.81 mM; Ultrasonic )
-
SMILESC[C@@H]1COCCN1c1cc(c2cnn(-c3cc[nH]n3)c2n1)[C@@]1(O)C[C@@H]2CC[C@H](C1)O2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anne Roulston, et al. RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. Mol Cancer Ther?
molnova catalog
related products
-
AZ20
AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.
-
BAY-1895344
BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency; potently inhibits the proliferation of a broad spectrum of human tumor cell lines with mean IC50 of 78 nM; inhibits hydroxyurea-induced H2AX phosphorylation, exhibits strong in vivo anti-tumor efficacy in monotherapy in a variety of xenograft models.Blood Cancer,Phase 1 Clinical
-
AZD1390
AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM.Brain Cancer,Phase 1 Clinical
